Search

Your search keyword '"Sturk, Auguste"' showing total 45 results
Start Over Author "Sturk, Auguste"
45 results on '"Sturk, Auguste"'

8. Obituary J. W. ten Cate

Author

Huisman, Menno V., primary, Levi, Marcel, additional, van Royen, Eric A., additional, Breederveld, Cees, additional, Büller, Harry R., additional, Peters, Marjolein, additional, Sturk, Auguste, additional, van Deventer, Sander J., additional, Avvisati, Giuseppe, additional, Prandoni, Paolo, additional, and Agnelli, Giancarlo, additional

Published
2021
Full Text
View/download PDF

10. List of Contributors

Author

Andrews, Robert K., primary, Aster, Richard H., additional, Atkinson, Ben T, additional, Barnard, Marc R., additional, Bavry, Anthony A., additional, Bayer, Arnold S., additional, Beaulieu, Lea M., additional, Berndt, Michael C., additional, Berny-Lang, Michelle A., additional, Bhatt, Deepak L., additional, Bizzaro, Nicola, additional, Bledzka, Kamila, additional, Bouchard, Beth A., additional, Brass, Lawrence F., additional, Bray, Paul F., additional, Briggs, Carol, additional, Bussel, James B., additional, Cattaneo, Marco, additional, Chakravorty, Subarna, additional, Chong, Beng H., additional, Clemetson, Jeannine, additional, Clemetson, Kenneth J., additional, Coller, Barry S., additional, Covic, Lidija, additional, Davì, Giovanni, additional, del Zoppo, Gregory J., additional, Dowling, Mark R., additional, Dubois, Christophe, additional, Eisert, Wolfgang G., additional, Evangelista, Virgilio, additional, Flaumenhaft, Robert, additional, Freedman, Jane E., additional, Freedman, John, additional, Frelinger, Andrew L., additional, Furie, Barbara C., additional, Furie, Bruce, additional, Gardiner, Chris, additional, Gawaz, Meinrad, additional, Geisler, Tobias, additional, Greinacher, Andreas, additional, Gurbel, Paul A., additional, Harrison, Paul, additional, Hartwig, John H., additional, Hayward, Catherine P.M., additional, Hughes, Craig E., additional, Ikeda, Yasuo, additional, Israels, Sara J., additional, Italiano, Joseph E., additional, Jackson, Shaun, additional, Jain, Shashank, additional, Jones, Chris I., additional, Josefsson, Emma C., additional, Kaplan, Cécile, additional, Kile, Benjamin T., additional, Kimura, Yukio, additional, Klement, Giannoula Lakka, additional, Kolandaivelu, Kumaran, additional, Kuliopulos, Athan, additional, Kuter, David J., additional, Lambert, Michelle P., additional, Langer, Harald F., additional, Lebois, Marion, additional, Levin, Jack, additional, Lordkipanidzé, Marie, additional, Ma, Yan-Qing, additional, Mannucci, Pier Mannuccio, additional, McCrae, Keith R., additional, Merrill-Skoloff, Glenn, additional, Michelson, Alan D., additional, Moffat, Karen A., additional, Mutch, Nicola J., additional, Newman, Debra K., additional, Newman, Peter E., additional, Ni, Heyu, additional, Nieuwland, Rienk, additional, Ouwehand, Willem H., additional, Parsons, Jeremy, additional, Patrono, Carlo, additional, Perrotta, Peter L., additional, Pesho, Michelle M., additional, Plow, Edward F., additional, Politt, Alice Y., additional, Poncz, Mortimer, additional, Poon, Man-Chiu, additional, Provost, Patrick, additional, Psaila, Bethan, additional, Rao, A. Koneti, additional, Rinder, Henry M., additional, Roberts, Irene A.G., additional, Rondina, Matthew T., additional, Ruggeri, Zaverio M., additional, Santilli, Francesca, additional, Schwertz, Hansjörg, additional, Shai, Ela, additional, Silveira, Jay R., additional, Smith, Brian R., additional, Smith, Matthew C., additional, Smyth, Susan S., additional, Snyder, Edward L., additional, Sobel, Michael, additional, Soranzo, Nicole, additional, Stalker, Timothy J., additional, Sturk, Auguste, additional, Sudo, Toshiki, additional, Sullivan, Spencer, additional, Tantry, Udaya S., additional, Tefferi, Ayalew, additional, Tracy, Paul B., additional, Tsai, Han-Mou, additional, van der Pol, Edwin, additional, Varon, David, additional, Vazzana, Natale, additional, Vieira-de-Abreu, Adriana, additional, Wannemacher, Kenneth, additional, Ware, Jerry, additional, Warkentin, Theodore E., additional, Watson, Steve P., additional, Weyrich, Andrew S., additional, White, James G., additional, Wilcox, David A., additional, Yeaman, Michael R., additional, Zhang, Ping, additional, Zhu, Li, additional, and Zimmerman, Guy A., additional

Published
2013
Full Text
View/download PDF

13. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction

Author

Gasecka, Aleksandra, primary, Nieuwland, Rienk, additional, Budnik, Monika, additional, Dignat-George, Françoise, additional, Eyileten, Ceren, additional, Harrison, Paul, additional, Huczek, Zenon, additional, Kapłon-Cieślicka, Agnieszka, additional, Lacroix, Romaric, additional, Opolski, Grzegorz, additional, Pluta, Kinga, additional, van der Pol, Edwin, additional, Postuła, Marek, additional, Leroyer, Aurélie, additional, Siljander, Pia, additional, Sturk, Auguste, additional, and Filipiak, Krzysztof J., additional

Published
2018
Full Text
View/download PDF

15. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction.

Author

Gasecka, Aleksandra, Nieuwland, Rienk, Budnik, Monika, Dignat-George, Françoise, Eyileten, Ceren, Harrison, Paul, Huczek, Zenon, Kapłon-Cieślicka, Agnieszka, Lacroix, Romaric, Opolski, Grzegorz, Pluta, Kinga, van der Pol, Edwin, Postuła, Marek, Leroyer, Aurélie, Siljander, Pia, Sturk, Auguste, and Filipiak, Krzysztof J.

Subjects
PRASUGREL, RANDOMIZED controlled trials, MYOCARDIAL infarction, PERCUTANEOUS coronary intervention, BLOOD platelet aggregation, THROMBOTIC thrombocytopenic purpura
Abstract

Activated platelets contribute to thrombosis and inflammation by the release of extracellular vesicles (EVs) exposing P-selectin, phosphatidylserine (PS) and fibrinogen. P2Y12 receptor antagonists are routinely administered to inhibit platelet activation in patients after acute myocardial infarction (AMI), being a combined antithrombotic and anti-inflammatory therapy. The more potent P2Y12 antagonist ticagrelor improves cardiovascular outcome in patients after AMI compared to the less potent clopidogrel, suggesting that greater inhibition of platelet aggregation is associated with better prognosis. The effect of ticagrelor and clopidogrel on the release of EVs from platelets and other P2Y12-exposing cells is unknown. This study compares the effects of ticagrelor and clopidogrel on (1) the concentrations of EVs from activated platelets (primary end point), (2) the concentrations of EVs exposing fibrinogen, exposing PS, from leukocytes and from endothelial cells (secondary end points) and (3) the procoagulant activity of plasma EVs (tertiary end points) in 60 consecutive AMI patients. After the percutaneous coronary intervention, patients will be randomized to antiplatelet therapy with ticagrelor (study group) or clopidogrel (control group). Blood will be collected from patients at randomization, 48 hours after randomization and 6 months following the index hospitalization. In addition, 30 age- and gender-matched healthy volunteers will be enrolled in the study to investigate the physiological concentrations and procoagulant activity of EVs using recently standardized protocols and EV-dedicated flow cytometry. Concentrations of EVs will be determined by flow cytometry. Procoagulant activity of EVs will be determined by fibrin generation test. The compliance and response to antiplatelet therapy will be assessed by impedance aggregometry. We expect that plasma from patients treated with ticagrelor (1) contains lower concentrations of EVs from activated platelets, exposing fibrinogen, exposing PS, from leukocytes and from endothelial cells and (2) has lower procoagulant activity, when compared to patients treated with clopidogrel. Antiplatelet therapy effect on EVs may identify a new mechanism of action of ticagrelor, as well as create a basis for future studies to investigate whether lower EV concentrations are associated with improved clinical outcomes in patients treated with P2Y12 antagonists. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

24. Development of Peritoneal Carcinomatosis in Epithelial Ovarian Cancer: A Review.

Author

van Baal, Juliette O. A. M., van Noorden, Cornelis J. F., Nieuwland, Rienk, Van de Vijver, Koen K., Sturk, Auguste, van Driel, Willemien J., Kenter, Gemma G., and Lok, Christianne A. R.

Subjects
PERITONEAL cancer, OVARIAN epithelial cancer, PROGNOSIS, PERITONEUM, IMMUNOHISTOCHEMISTRY
Abstract

Epithelial ovarian cancer (EOC) metastasizes intra-abdominally with often numerous, superficial, small-sized lesions. This so-called peritoneal carcinomatosis is difficult to treat, and peritoneal recurrences are frequently observed, leading to a poor prognosis. Underlying mechanisms of interactions between EOC and peritoneal cells are incompletely understood. This review summarizes and discusses the development of peritoneal carcinomatosis from a cell-biological perspective, focusing on characteristics of EOC and peritoneal cells. We aim to provide insight into how peritoneum facilitates tumor adhesion but limits size of lesions and depth of invasion. The development of peritoneal carcinomatosis is a multistep process that requires adaptations of EOC and peritoneal cells. Mechanisms that enable tumor adhesion and growth involve cadherin restructuring on EOC cells, integrin-mediated adhesion, and mesothelial evasion by mechanical forces driven by integrin-ligand interactions. Clinical trials targeting these mechanisms, however, showed only limited effects. Other factors that inhibit tumor growth and deep invasion are virtually unknown. Future studies are needed to elucidate the exact mechanisms that underlie the development and limited growth of peritoneal carcinomatosis. This review on development of peritoneal carcinomatosis of EOC summarizes the current knowledge and its limitations. Clarification of the stepwise process may inspire future research to investigate new treatment approaches of peritoneal carcinomatosis. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

25. Circulating Cell-Derived Microparticles in Recent-Onset Type 2 Diabetes: A Mediator of Atherogenesis?

Author

DIAMANT, MICHAELA, NIEUWLAND, RIENK, BERCKMANS, RENE J., PABLO, RENEE F., SMIT, JAN W. A., STURK, AUGUSTE, and RADDER, JASPER K.

Subjects
Diabetes -- Research, Health
Abstract

Microparticles (MP) are small vesicles released from blood- and endothelial cells during activation and apoptosis. In vivo circulating MP are procoagulant, due to exposure of phosphatidylserine and tissue factor (TF), [...]

Published
2000

26. Accuracy and Reproducibility in Quantification of Plasma Protein Concentrations by Mass Spectrometry without the Use of Isotopic Standards

Author

Kramer, Gertjan, primary, Woolerton, Yvonne, additional, van Straalen, Jan P., additional, Vissers, Johannes P. C., additional, Dekker, Nick, additional, Langridge, James I., additional, Beynon, Robert J., additional, Speijer, Dave, additional, Sturk, Auguste, additional, and Aerts, Johannes M. F. G., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results